Shield Therapeutics is an independent specialty pharmaceutical company focused on the development and commercialization of late-stage, mineral-derived hospital pharmaceuticals which address areas of high unmet medical need. The Company’s key products are Feraccru and PT20, one commercially available and one late-stage pharmaceutical for the treatment of iron deficiency anaemia and systemic phosphate accumulation, otherwise known as hyperphosphatemia.